bluebird bio, Inc. (BLUE) Scheduled to Post Earnings on Tuesday
bluebird bio, Inc. (NASDAQ:BLUE) is scheduled to be releasing its earnings data after the market closes on Tuesday, October 31st. Analysts expect bluebird bio to post earnings of ($1.68) per share for the quarter.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). The firm had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm’s revenue was up 977.4% on a year-over-year basis. During the same period last year, the business earned ($1.59) EPS. On average, analysts expect bluebird bio to post $-6.76 EPS for the current fiscal year and $-7.08 EPS for the next fiscal year.
bluebird bio, Inc. (NASDAQ BLUE) opened at 139.2844 on Tuesday. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $145.70. The firm’s 50-day moving average is $131.35 and its 200 day moving average is $104.71. The firm’s market cap is $6.35 billion.
In other news, Director Daniel Lynch sold 500 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the sale, the director now directly owns 3,300 shares of the company’s stock, valued at approximately $396,000. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Nick Leschly sold 10,823 shares of the company’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $145.05, for a total value of $1,569,876.15. Following the completion of the sale, the chief executive officer now directly owns 262,409 shares of the company’s stock, valued at $38,062,425.45. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 142,602 shares of company stock valued at $17,608,391. 3.90% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/24/bluebird-bio-inc-blue-scheduled-to-post-earnings-on-tuesday.html.
Several research analysts recently issued reports on BLUE shares. Jefferies Group LLC reiterated a “buy” rating on shares of bluebird bio in a research report on Thursday, July 6th. Zacks Investment Research upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and set a $118.00 price target on the stock in a research report on Tuesday, July 4th. BidaskClub downgraded shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 30th. BTIG Research reiterated a “buy” rating and set a $112.00 price target on shares of bluebird bio in a research report on Wednesday, June 28th. Finally, Janney Montgomery Scott set a $125.00 price target on shares of bluebird bio and gave the stock a “buy” rating in a research report on Monday, June 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. bluebird bio has a consensus rating of “Hold” and an average target price of $118.81.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.